Research peptide
PT-141
10 mg
Select size
$48.50CAD
Volume pricing
- Buy 2Save 5%$92.15 ($46.08 each)
- Buy 3Save 10%$130.95 ($43.65 each)
Applies to the total quantity in your cart.
Research material
Supplied in a sealed glass vial and labelled with a batch reference. Batch-specific documentation is available on request. For Research Use Only. Not for Human or Animal Use.
- Presentation
- 10 mg
- Container
- Sealed glass vial
- Batch reference
- Printed on every unit
- Documentation
- Batch-specific COA on request
- Research use
- For Research Use Only
Description
PT-141 (Bremelanotide) is an investigational synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist. Unlike phosphodiesterase-5 (PDE5) inhibitors such as sildenafil or tadalafil, which primarily influence erectile function through the vascular nitric-oxide pathway, bremelanotide acts through melanocortin signaling within the central nervous system.
FDA Access Data
Bremelanotide is particularly notable because it is the active pharmaceutical ingredient in Vyleesi, which the FDA approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
The FDA-approved indication is specific; it is not an FDA-approved treatment for male erectile dysfunction or general sexual-performance enhancement. U.S. Food and Drug Administration
Research has investigated melanocortin signaling in relation to sexual desire, arousal and reproductive neurobiology, with bremelanotide also studied in other populations and sexual-function disorders.
At Kinetus Biolabs, PT-141 is positioned as a research compound for investigating melanocortin receptor biology, central sexual-function signaling and neuroendocrine pathways.
Kinetus Biolabs | Precision Science. Peak Potential.
Research Use Only — Not for Human Consumption.
